Aktie GENOMIC HEALTH, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Genomic Health, Inc.

Aktien

US37244C1018

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
MDxHealth SA acquired Oncotype DX GPS Prostate Cancer Business from Genomic Health, Inc. for approximately $100 million.
Biocartis Group NV and Biocartis and Genomic Health, Inc. Agree to End Collaboration Due to Changed Market Circumstances
Genomic Health, Inc. Announces Executive Changes
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from S&P 1000
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from S&P 600 Health Care
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from S&P 600
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from S&P Global BMI Index
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from S&P Composite 1500
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from S&P TMI Index
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from S&P Biotechnology Select Industry Index
Genomic Health, Inc.(NasdaqGM:GHDX) dropped from NASDAQ Composite Index
Exact Sciences Corporation completed the acquisition of Exact Sciences Corporation from Baker Bros. Advisors LP and others.
Genomic Health : Stockholders Approve Proposed Acquisition by Exact Sciences
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from NASDAQ Biotechnology Index
Genomic Health Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019
Genomic Health : New TAILORx Data, Published Today in JAMA Oncology, Add to Strong Evidence Base Reinforcing Unique Ability of Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy Treatment
Genomic Health, Inc. Announces Results from a New Analysis of the Trial Assigning IndividuaLised Options for Treatment (Rx), or TAILORx
Genomic Health : New St. Gallen International Breast Cancer Guidelines Recommend Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy for Node-negative and Node-positive Early-stage Breast Cancer
New St. Gallen International Breast Cancer Guidelines Recommends Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy for Node-negative and Node-positive Early-stage Breast Cancer
WeissLaw LLP Investigates Genomic Health, Inc.
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. Aktie
  4. Nachrichten Genomic Health, Inc.
  5. Andere Sprachen